Personal tools

Coexpression cluster:C191

From FANTOM5_SSTAR

Revision as of 14:33, 12 September 2012 by Autoedit (talk | contribs)
Jump to: navigation, search


Full id: C191_leiomyoblastoma_Mast_parietal_acute_bone_neuroepithelioma_embryonic



Phase1 CAGE Peaks

Hg19::chr10:119217804..119217808,-p@chr10:119217804..119217808
-
Hg19::chr11:11199184..11199203,+p@chr11:11199184..11199203
+
Hg19::chr11:11204475..11204502,+p@chr11:11204475..11204502
+
Hg19::chr11:11204503..11204513,+p@chr11:11204503..11204513
+
Hg19::chr11:11204661..11204666,+p@chr11:11204661..11204666
+
Hg19::chr11:11204710..11204723,+p@chr11:11204710..11204723
+
Hg19::chr11:11239563..11239568,+p@chr11:11239563..11239568
+
Hg19::chr11:11261470..11261474,+p1@MTND5P21
Hg19::chr11:11267941..11267951,+p@chr11:11267941..11267951
+
Hg19::chr11:11280165..11280169,+p@chr11:11280165..11280169
+
Hg19::chr11:11306477..11306480,+p@chr11:11306477..11306480
+
Hg19::chr12:92402520..92402535,-p@chr12:92402520..92402535
-
Hg19::chr14:102701899..102701936,-p6@MOK
Hg19::chr14:85975105..85975111,-p@chr14:85975105..85975111
-
Hg19::chr14:85982823..85982842,+p@chr14:85982823..85982842
+
Hg19::chr15:47476379..47476409,+p6@SEMA6D
Hg19::chr15:47476835..47476844,-p@chr15:47476835..47476844
-
Hg19::chr15:47476886..47476899,-p@chr15:47476886..47476899
-
Hg19::chr15:95294364..95294378,+p@chr15:95294364..95294378
+
Hg19::chr15:96037007..96037012,-p1@ENST00000554412
Hg19::chr15:96390170..96390194,+p@chr15:96390170..96390194
+
Hg19::chr17:27044011..27044042,-p@chr17:27044011..27044042
-
Hg19::chr17:54711126..54711143,-p@chr17:54711126..54711143
-
Hg19::chr17:54711165..54711172,-p@chr17:54711165..54711172
-
Hg19::chr17:54711180..54711190,-p@chr17:54711180..54711190
-
Hg19::chr18:6683449..6683456,+p@chr18:6683449..6683456
+
Hg19::chr19:46628057..46628066,-p2@IGFL3
Hg19::chr19:49014956..49014973,-p4@AB384647
Hg19::chr1:170283847..170283854,-p@chr1:170283847..170283854
-
Hg19::chr1:170285936..170285978,+p@chr1:170285936..170285978
+
Hg19::chr1:19992392..19992403,+p5@HTR6
Hg19::chr1:26349001..26349015,+p@chr1:26349001..26349015
+
Hg19::chr1:90308844..90308857,+p36@LRRC8D
Hg19::chr20:31647705..31647739,+p@chr20:31647705..31647739
+
Hg19::chr2:196313239..196313248,+p1@ENST00000413290
Hg19::chr2:218290216..218290256,-p@chr2:218290216..218290256
-
Hg19::chr2:234826016..234826024,+p1@TRPM8
Hg19::chr2:234992199..234992202,-p@chr2:234992199..234992202
-
Hg19::chr2:66662797..66662818,+p10@MEIS1
Hg19::chr2:68019731..68019735,-p@chr2:68019731..68019735
-
Hg19::chr2:68054768..68054773,-p@chr2:68054768..68054773
-
Hg19::chr2:68280395..68280440,-p4@C1D
Hg19::chr2:71776374..71776384,+p@chr2:71776374..71776384
+
Hg19::chr2:97572846..97572862,-p@chr2:97572846..97572862
-
Hg19::chr3:30199912..30199921,+p@chr3:30199912..30199921
+
Hg19::chr3:30414583..30414594,+p@chr3:30414583..30414594
+
Hg19::chr3:80101031..80101042,+p@chr3:80101031..80101042
+
Hg19::chr3:85868272..85868282,-p@chr3:85868272..85868282
-
Hg19::chr3:85868324..85868358,-p@chr3:85868324..85868358
-
Hg19::chr4:157997240..157997259,+p2@GLRB
Hg19::chr4:157998021..157998028,-p@chr4:157998021..157998028
-
Hg19::chr4:158186667..158186674,-p@chr4:158186667..158186674
-
Hg19::chr4:168728249..168728254,-p@chr4:168728249..168728254
-
Hg19::chr4:54886472..54886506,+p@chr4:54886472..54886506
+
Hg19::chr5:167089089..167089121,+p@chr5:167089089..167089121
+
Hg19::chr5:23687537..23687541,+p@chr5:23687537..23687541
+
Hg19::chr5:23797853..23797862,-p@chr5:23797853..23797862
-
Hg19::chr5:24083424..24083429,+p@chr5:24083424..24083429
+
Hg19::chr6:133275530..133275540,+p@chr6:133275530..133275540
+
Hg19::chr6:133275544..133275556,+p@chr6:133275544..133275556
+
Hg19::chr6:133275558..133275575,+p@chr6:133275558..133275575
+
Hg19::chr6:133275582..133275585,+p@chr6:133275582..133275585
+
Hg19::chr6:133275614..133275622,+p@chr6:133275614..133275622
+
Hg19::chr6:133294363..133294364,+p@chr6:133294363..133294364
+
Hg19::chr6:33140464..33140471,-p@chr6:33140464..33140471
-
Hg19::chr6:36906253..36906260,-p@chr6:36906253..36906260
-
Hg19::chr6:75462110..75462112,-p@chr6:75462110..75462112
-
Hg19::chr6:91296707..91296721,-p3@MAP3K7
Hg19::chr6:91296737..91296821,-p1@MAP3K7
Hg19::chr6:91405526..91405531,-p@chr6:91405526..91405531
-
Hg19::chr6:91405535..91405543,-p@chr6:91405535..91405543
-
Hg19::chr6:91602280..91602289,+p@chr6:91602280..91602289
+
Hg19::chr6:91705096..91705099,+p@chr6:91705096..91705099
+
Hg19::chr7:16569917..16569927,-p9@SOSTDC1
Hg19::chr7:47648038..47648043,+p@chr7:47648038..47648043
+
Hg19::chr7:47833069..47833071,+p@chr7:47833069..47833071
+
Hg19::chr7:8474731..8474740,+p8@NXPH1
Hg19::chr7:8474792..8474799,+p30@NXPH1
Hg19::chr7:8474804..8474815,+p15@NXPH1
Hg19::chr7:8474817..8474830,+p10@NXPH1
Hg19::chr7:8523611..8523616,+p@chr7:8523611..8523616
+
Hg19::chr8:99264813..99264821,-p18@NIPAL2
Hg19::chr9:3983221..3983226,+p@chr9:3983221..3983226
+
Hg19::chr9:4117869..4117882,-p12@GLIS3
Hg19::chrX:12887946..12887949,-p@chrX:12887946..12887949
-
Hg19::chrX:12964086..12964118,-p@chrX:12964086..12964118
-
Hg19::chrX:25718317..25718324,-p@chrX:25718317..25718324
-
Hg19::chrX:25873187..25873209,+p@chrX:25873187..25873209
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

GO IDGO nameFDR corrected p-value
GO:0016594glycine binding0.0377342316088888
GO:0016934extracellular-glycine-gated chloride channel activity0.0377342316088888
GO:0002711positive regulation of T cell mediated immunity0.0377342316088888
GO:0032743positive regulation of interleukin-2 production0.0377342316088888
GO:0002726positive regulation of T cell cytokine production0.0377342316088888
GO:0001964startle response0.0377342316088888
GO:0016933extracellular-glycine-gated ion channel activity0.0377342316088888
GO:0002369T cell cytokine production0.0377342316088888
GO:0002724regulation of T cell cytokine production0.0377342316088888
GO:0002702positive regulation of production of molecular mediator of immune response0.0377342316088888
GO:0002720positive regulation of cytokine production during immune response0.0377342316088888
GO:0002709regulation of T cell mediated immunity0.0377342316088888
GO:0032663regulation of interleukin-2 production0.0377342316088888
GO:0002824positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains0.0377342316088888
GO:0002718regulation of cytokine production during immune response0.0377342316088888
GO:0002821positive regulation of adaptive immune response0.0377342316088888
GO:0002700regulation of production of molecular mediator of immune response0.0377342316088888
GO:0002367cytokine production during immune response0.0377342316088888
GO:0002705positive regulation of leukocyte mediated immunity0.0377342316088888
GO:0002456T cell mediated immunity0.0377342316088888
GO:0002708positive regulation of lymphocyte mediated immunity0.0377342316088888
GO:0002699positive regulation of immune effector process0.0377342316088888
GO:0003702RNA polymerase II transcription factor activity0.0377342316088888
GO:0004969histamine receptor activity0.0377342316088888
GO:0007250activation of NF-kappaB-inducing kinase0.0377342316088888
GO:0002703regulation of leukocyte mediated immunity0.0377342316088888
GO:0002706regulation of lymphocyte mediated immunity0.0377342316088888
GO:0007268synaptic transmission0.0377342316088888
GO:0002819regulation of adaptive immune response0.0377342316088888
GO:0002822regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains.0.0377342316088888
GO:0002697regulation of immune effector process0.0421213614924425
GO:0019226transmission of nerve impulse0.0448298461578829
GO:0050852T cell receptor signaling pathway0.0448298461578829
GO:0004709MAP kinase kinase kinase activity0.0460633558676464
GO:0016597amino acid binding0.0493592702435223
GO:0032501multicellular organismal process0.0493592702435223
GO:0032623interleukin-2 production0.0493592702435223



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br><br>uberon_data<br><br>

Uber Anatomy
Ontology termp-valuen
regional part of nervous system6.57e-2794
nervous system6.57e-2794
central nervous system1.49e-2682
neural tube9.90e-2357
neural rod9.90e-2357
future spinal cord9.90e-2357
neural keel9.90e-2357
brain3.35e-2169
future brain3.35e-2169
regional part of brain2.16e-2059
regional part of forebrain2.25e-2041
forebrain2.25e-2041
future forebrain2.25e-2041
anterior neural tube2.53e-1942
gray matter1.66e-1834
brain grey matter1.66e-1834
cerebral hemisphere7.32e-1832
telencephalon9.11e-1834
neurectoderm3.28e-1790
regional part of telencephalon3.77e-1733
neural plate2.32e-1686
presumptive neural plate2.32e-1686
ectoderm3.48e-16173
presumptive ectoderm3.48e-16173
ectoderm-derived structure2.28e-15169
regional part of cerebral cortex6.56e-1522
cerebral cortex2.54e-1425
pallium2.54e-1425
neocortex1.00e-1320
adult organism1.74e-13115
pre-chordal neural plate1.41e-1061
anterior region of body2.03e-10129
craniocervical region2.03e-10129
head5.39e-10123


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=Coexpression_cluster:C191&oldid=2136538"